| 14.21 0.09 (0.64%) | 10-24 15:01 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.22 | 1-year : | 21.28 |
| Resists | First : | 15.6 | Second : | 18.22 |
| Pivot price | 14.18 |
|||
| Supports | First : | 13.61 | Second : | 12.38 |
| MAs | MA(5) : | 14.41  |
MA(20) : | 14.02 |
| MA(100) : | 11.61 |
MA(250) : | 12.3 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 43.1 |
D(3) : | 51.1 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 24.15 | Low : | 6.42 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TYRA ] has closed below upper band by 48.2%. Bollinger Bands are 23.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.25 - 14.33 | 14.33 - 14.4 |
| Low: | 13.54 - 13.64 | 13.64 - 13.74 |
| Close: | 13.97 - 14.12 | 14.12 - 14.26 |
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Fri, 24 Oct 2025
Historical volatility pattern of Tyra Biosciences Inc. visualized - 2025 Investor Takeaways & Smart Money Movement Tracker - newser.com
Wed, 22 Oct 2025
Signal strength of Tyra Biosciences Inc. stock in tech scanners - July 2025 Catalysts & Daily Risk Controlled Trade Plans - newser.com
Wed, 22 Oct 2025
Is Tyra Biosciences Inc. stock poised for growth - Rate Cut & Consistent Return Strategy Ideas - newser.com
Tue, 21 Oct 2025
Is Tyra Biosciences Inc. stock poised for growth - Quarterly Portfolio Report & Stepwise Trade Signal Implementation - newser.com
Tue, 21 Oct 2025
Is Tyra Biosciences Inc. stock poised for growth - Recession Risk & Fast Moving Stock Watchlists - newser.com
Mon, 20 Oct 2025
Signal strength of Tyra Biosciences Inc. stock in tech scanners - Market Weekly Review & Low Volatility Stock Suggestions - newser.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 106.5 (%) |
| Shares Short | 5,920 (K) |
| Shares Short P.Month | 5,920 (K) |
| EPS | -1.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.3 % |
| Return on Equity (ttm) | -31.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -7.95 |
| PEG Ratio | 0 |
| Price to Book value | 2.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|